CA2956256A1 - Methods and compositions relating to treatment of pulmonary arterial hypertension - Google Patents

Methods and compositions relating to treatment of pulmonary arterial hypertension Download PDF

Info

Publication number
CA2956256A1
CA2956256A1 CA2956256A CA2956256A CA2956256A1 CA 2956256 A1 CA2956256 A1 CA 2956256A1 CA 2956256 A CA2956256 A CA 2956256A CA 2956256 A CA2956256 A CA 2956256A CA 2956256 A1 CA2956256 A1 CA 2956256A1
Authority
CA
Canada
Prior art keywords
tgf
beta
pulmonary
tgfbrii
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2956256A
Other languages
English (en)
French (fr)
Inventor
Lai-Ming Yung
Paul B. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CA2956256A1 publication Critical patent/CA2956256A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
CA2956256A 2014-08-01 2015-08-03 Methods and compositions relating to treatment of pulmonary arterial hypertension Pending CA2956256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031924P 2014-08-01 2014-08-01
US62/031,924 2014-08-01
PCT/US2015/043373 WO2016019368A1 (en) 2014-08-01 2015-08-03 Methods and compositions relating to treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
CA2956256A1 true CA2956256A1 (en) 2016-02-04

Family

ID=55218399

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2956256A Pending CA2956256A1 (en) 2014-08-01 2015-08-03 Methods and compositions relating to treatment of pulmonary arterial hypertension

Country Status (7)

Country Link
US (3) US20170202918A1 (cg-RX-API-DMAC7.html)
EP (2) EP3174550B1 (cg-RX-API-DMAC7.html)
JP (2) JP6955443B2 (cg-RX-API-DMAC7.html)
CN (2) CN106794233B (cg-RX-API-DMAC7.html)
AU (3) AU2015296037B2 (cg-RX-API-DMAC7.html)
CA (1) CA2956256A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016019368A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106978485A (zh) * 2017-03-22 2017-07-25 首都医科大学 卵泡抑素样蛋白1对肺动脉高压的保护作用
CN109311970A (zh) * 2016-06-08 2019-02-05 Ucb生物制药私人有限公司 结合人TGF-β1、人TGF-β2和人TGF-β3的拮抗性抗体及其用于治疗肺纤维化的用途
CN115192719A (zh) * 2016-05-26 2022-10-18 匹兹堡大学联邦高等教育系统 Gls1抑制组合物在治疗肺血管疾病中的应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
FI3628049T3 (fi) 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
CN109701033A (zh) * 2018-05-04 2019-05-03 遵义医学院附属医院 靶向沉默klf4基因的重组腺相关病毒的应用
US20220339248A1 (en) * 2019-06-19 2022-10-27 The Research Foundation For The State University Of New York Methods for treating neointimal hyperlasia using f11r/jam-a inhibitors
AU2020315599A1 (en) * 2019-07-15 2022-02-10 Yale University Methods and compositions for treating pulmonary arterial hypertension
GB202006072D0 (en) * 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
JP2023542298A (ja) * 2020-09-11 2023-10-06 プルモシム セラピューティクス リミテッド ライアビリティ カンパニー 肺高血圧症を治療又は予防する組成物及び方法
TW202513078A (zh) * 2023-06-06 2025-04-01 科進製藥科技股份有限公司 以７－脫氫膽固醇或其鹽、氧化物、代謝物或衍生物用於預防或治療肺動脈高壓的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0975771B1 (en) 1997-04-18 2007-07-11 Biogen Idec MA Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AU4572899A (en) 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) * 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
AU2003273991A1 (en) 2002-10-14 2004-05-04 Michelin Recherche Et Technique S.A. Extended mobility tyre comprising bead with symmetrical force distribution
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0514259D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Pharmaceutical compositions
US20070088597A1 (en) * 2005-10-19 2007-04-19 Project Match Families In Transition Method of tracking social services
US20080009500A1 (en) 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP2029625A2 (en) 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
CN100588717C (zh) * 2007-03-21 2010-02-10 中国医学科学院阜外心血管病医院 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途
ATE520682T1 (de) * 2007-08-22 2011-09-15 Irm Llc 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren
EP2037275A1 (en) * 2007-09-11 2009-03-18 F. Hoffmann-La Roche AG Differentiation of different causes of right heart failure
KR101008385B1 (ko) * 2008-08-01 2011-01-14 한국과학기술연구원 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
US20110172296A1 (en) * 2010-01-12 2011-07-14 Bennett C Frank Modulation of transforming growth factor-beta 1 expression
EP2372364A1 (en) * 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20130287688A1 (en) * 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012093125A1 (en) * 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
CN108341863A (zh) 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
SG194901A1 (en) * 2011-05-09 2013-12-30 Univ Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
MX351600B (es) * 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
CA2843535C (en) 2011-08-01 2021-04-06 Tufts Medical Center, Inc. Treatment of cardiac diseases and fibrosis with endoglin receptor antibodies and antigen-binding fragments thereof
CN102321173B (zh) * 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2915627A1 (en) * 2012-06-15 2013-12-19 The General Hospital Corporation Inhibitors of micrornas that regulate production of atrial natriuretic peptide (anp) as therapeutics and uses thereof
EP2597466A1 (en) * 2012-06-26 2013-05-29 Roche Diagniostics GmbH Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients
EP2900263B1 (en) * 2012-09-26 2019-06-05 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
CN111100197B (zh) * 2013-01-17 2024-11-15 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
KR101346181B1 (ko) * 2013-02-18 2014-01-03 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12
KR101346132B1 (ko) * 2013-02-18 2013-12-31 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) * 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
CN113817672A (zh) 2014-05-18 2021-12-21 儿童医学中心公司 涉及外排体的方法和组合物
CA2952061A1 (en) * 2014-06-13 2015-12-17 Novartis Ag Use of serelaxin to reduce gdf-15
US20170137505A1 (en) * 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192719A (zh) * 2016-05-26 2022-10-18 匹兹堡大学联邦高等教育系统 Gls1抑制组合物在治疗肺血管疾病中的应用
US11672795B2 (en) 2016-05-26 2023-06-13 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
CN115192719B (zh) * 2016-05-26 2024-03-01 匹兹堡大学联邦高等教育系统 用于治疗肺血管疾病的组合物和方法
CN109311970A (zh) * 2016-06-08 2019-02-05 Ucb生物制药私人有限公司 结合人TGF-β1、人TGF-β2和人TGF-β3的拮抗性抗体及其用于治疗肺纤维化的用途
US11518803B2 (en) 2016-06-08 2022-12-06 UCB Biopharma SRL Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
CN106978485A (zh) * 2017-03-22 2017-07-25 首都医科大学 卵泡抑素样蛋白1对肺动脉高压的保护作用

Also Published As

Publication number Publication date
US20190365857A1 (en) 2019-12-05
CN114470207B (zh) 2023-09-19
AU2015296037A1 (en) 2017-02-16
US20210322548A1 (en) 2021-10-21
AU2021203515A1 (en) 2021-07-08
US11027014B2 (en) 2021-06-08
US12472251B2 (en) 2025-11-18
JP2020125353A (ja) 2020-08-20
CN114470207A (zh) 2022-05-13
JP2017523200A (ja) 2017-08-17
JP6955443B2 (ja) 2021-10-27
EP3693004A1 (en) 2020-08-12
CN106794233A (zh) 2017-05-31
WO2016019368A1 (en) 2016-02-04
US20170202918A1 (en) 2017-07-20
EP3174550B1 (en) 2020-01-29
AU2015296037B2 (en) 2021-04-29
CN106794233B (zh) 2021-11-12
AU2024220131A1 (en) 2024-10-24
EP3174550A1 (en) 2017-06-07
EP3174550A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
US12472251B2 (en) Method for treating fibrosis with an anti-GDF-15 antibody
Yung et al. A selective transforming growth factor-β ligand trap attenuates pulmonary hypertension
US11643459B2 (en) TGFβ1-binding immunoglobulins and use thereof
CA2775793A1 (en) Siglec 15 antibodies in treating bone loss-related disease
JP2023501686A (ja) 線維性疾患の予防及び処置のための抗クローディン－１モノクローナル抗体。
EP3142699A1 (en) Compositions and methods for treating metabolic disorders
US11136383B2 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
US20240199755A1 (en) Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
DK2904009T3 (en) RELATIONSHIPS FOR TREATING THE REMYELINIZATION BLOCK IN DISEASES RELATED TO THE EXPRESSION OF HERV-W COAT PROTEIN
US20120244169A1 (en) Treatment for Radiation-Induced Disorders
WO2012071648A1 (en) Egfr antagonist for the treatment of heart disease
JP2008222603A (ja) 神経変性疾患の予防・治療剤
HK1233509A1 (en) Methods and compositions relating to treatment of pulmonary arterial hypertension
HK1233509B (en) Methods and compositions relating to treatment of pulmonary arterial hypertension
WO2016121680A1 (ja) 進行性骨化性線維異形成症治療剤
US10131707B2 (en) Treatment of sepsis and septic shock
KR20230054413A (ko) 당뇨병 치료 및 베타 세포 재생을 위한 방법 및 조성물
US10987343B2 (en) Compositions and methods for treating pulmonary diseases
WO2024112749A1 (en) Methods of treating heart failure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619

EEER Examination request

Effective date: 20200619